Kymriah pioneer Carl June is back, with first US human evidence for CRISPR use in cancer
At last: Some proof.
Eight years after the first CRISPR paper appeared in Science and after eight years of wrangling over the technology’s potential, University of Pennsylvania researchers have published some of the first evidence it can be used safely in cancer patients.
The small study, published yesterday in Science, is the first peer-reviewed findings in the US showing CRISPR can safely be used in humans. Vertex and CRISPR Therapeutics also announced positive results from a sickle cell patient and a beta thalassemia patient in November, but they have yet to publish. Unlike the Penn researchers, Vertex and CRISPR claimed they showed both efficacy and safety results.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,500+ biopharma pros reading Endpoints daily — and it's free.